AAO 2023: Clinical Insights From New Data on Age-Related Macular Degeneration

Vaidehi S. Dedania, MD

November 27, 2023

Vaidehi S. Dedania, MD, considers the practical implications of data presented at AAO 2023 on the management of patients with age-related macular degeneration.

Dr Dedania remarks on the value of the post hoc analyses of TENAYA and LUCERNE in confirming the benefits of faricimab, suggesting its appropriate use even earlier in a treatment course. The results of the GALE and GATHER2 studies offer patients more data on the increasing treatment effects over time and the safety and efficacy of avacincaptad pegol. Dr Dedania concludes with noting the promise of novel research, including data on tyrosine kinase inhibitors, TIE pathway inhibitors, and gene therapy for wet AMD.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: AAO 2023: Clinical Insights From New Data on Age-Related Macular Degeneration - Medscape - Nov 27, 2023.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....

AAO 2023: Clinical Insights From New Data on Age-Related Macular Degeneration

Tables

Authors and Disclosures

Authors and Disclosures

Expert

Vaidehi S. Dedania, MD

Comments

Email This

Feedback